• Teva Pharmaceutical Industries Ltd., of Jerusalem, and Lonza Group, of Basel, Switzerland, said they decided to discontinue their collaboration for the development, manufacturing and marketing of biosimilars following a strategic review of the Teva-Lonza Joint Venture.